On 2/4, at the Grace Global Raffles building in Singapore, Cellcare Holdings Pte. Ltd., Cellresearch Corporation Pte. Ltd., and Cellcare Laboratory Sdn. Bhd. signed a strategic cooperation agreement in stem cell technology. The event brought together scientists, biomedical experts, and regional healthcare representatives, connecting research, technology transfer, and practical healthcare applications.

This cooperation focuses on research and technology transfer of umbilical cord membrane stem cells, a promising approach in regenerative medicine. The initiative seeks to progressively bring scientific achievements closer to practical application, in accordance with each country's regulations.

Under the agreement, the three parties will coordinate to establish a comprehensive stem cell ecosystem. Cellresearch Corporation Pte. Ltd. will manage core technology research and transfer; Cellcare Holdings Pte. Ltd. will develop the ecosystem and expand market reach; and Cellcare Laboratory Sdn. Bhd. will oversee production, laboratory operations, and commercialization efforts.

Ms. Le Anh Tuyet, representative of the Board of Directors of Cellcare Holdings, signs a cooperation agreement with Mr. Ivor J Lim, Founding Director and Medical Director of CellResearch Corporation Group. Photo: Cellcare Holdings

At the event, a Cellcare Holdings representative stated that for advanced medical technology to transition into practice, three elements are essential: investment resources, a robust research foundation, and effective implementation capabilities.

This signing ceremony marks an initial step to integrate these elements, aiming to create sustainable value for the community.

From a research perspective, Ivor J Lim, Founding Director and Medical Director of CellResearch Corporation, highlighted the company's over 22 years of experience in research and development. This extensive work has built a strong scientific foundation and research data, enabling the development of stem cell technologies that adhere to professional standards and market regulations.

"As scientists and doctors, Associate Professor Phan Toan Thang and I focus on research and innovation. However, for research results to be progressively implemented in practice, we need partners capable of implementation and ecosystem development," Lim shared.

According to Lim, this three-party cooperation provides a foundation to advance technology applications in key markets such as Singapore, Malaysia, and Vietnam, while complying with specialized regulations in each country.

The signing ceremony creates a comprehensive ecosystem from research to application, aiming for sustainable treatment outcomes. Photo: Cellcare Holdings

Associate Professor, Doctor, Physician Phan Toan Thang is a Vietnamese scientist with significant contributions to stem cell research. He holds a patent granted by the United States Patent and Trademark Office (USPTO) for umbilical cord membrane stem cell technology. This technology is currently protected in over 50 countries and territories, including Vietnam.

Since 2004, upon returning to Singapore, Associate Professor, Doctor, Physician Phan Toan Thang has continued his in-depth research into the potential of stem cells in regenerative medicine. His studies focus on the biological characteristics of the umbilical cord membrane, which has opened a new approach in researching and developing tissue regeneration applications.

This research direction underpins the concept of "0-year-old" stem cells, attracting interest from the scientific community in regenerative medicine.

In Vietnam, Associate Professor, Doctor, Physician Phan Toan Thang currently serves as an advisory expert for Longevity Medical, a healthcare provider focused on developing proactive and personalized healthcare models.

Associate Professor Phan Toan Thang's (third from left) stem cell research is gradually being realized for disease treatment. Photo: Cellcare Holdings

At the event, Associate Professor Phan Toan Thang noted that stem cell research has seen many advancements over the years. However, a major challenge remains: how to transition scientific achievements into practical healthcare applications.

He believes that forming an ecosystem that connects research, implementation, and market development will help narrow the gap between laboratory discoveries and real-world applications.

"Umbilical cord membrane stem cell technology opens a new approach in regenerative medicine research, with the potential to be further developed and applied in the future according to professional standards and regulations in each country," he shared.

According to Associate Professor, Doctor, Physician Phan Toan Thang, with a scientific foundation, the participation of specialized units, and a clear development direction, the signing event on 2/4 in Singapore is expected to foster stronger connections between research and practice, progressively bringing scientific progress closer to the community.

Cellcare Holdings, headquartered in Singapore, operates in regenerative and proactive healthcare. Its ecosystem includes clinics, laboratories, and product development leveraging technologies such as stem cells and exosomes.

CellResearch Pte. Ltd, also based in Singapore, is a biotechnology research and development unit, specializing in umbilical cord matrix stem cells. The company possesses a proprietary technology platform and culture process, playing a role in technology transfer and supporting clinical application implementation in international markets.

Cellcare Laboratory in Johor Bahru, Malaysia, is a certified laboratory for the commercial culturing, production, and testing of stem cells. It serves as the center for practical implementation of transferred technologies, providing standard cells for medical use.

The Dan